Répertoire du corps professoral
Serge Rivest
Professeur titulaire
(418) 656-4141, poste 46236
serge.rivest@fmed.ulaval.ca
Pavillon Ferdinand-Vandry
1050, avenue de la Médecine
Local T3-67
Chaire de recherche du Canada en neuroimmunologie
Programme: Chaires de recherche du Canada - Fonctionnement
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2023
au30 juin 2030
Chercheur d'un jour
Programme: PromoScience
Organisme(s) subventionnaire(s): Conseil de recherches en sciences naturelles et génie Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 janvier 2023
au31 décembre 2025
Therapeutic properties of innate immune cells and system for brain diseases
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2022
au31 mars 2025
Acquisition d’équipements pour les activités de recherche en oncologie de précision au Nouveau Complexe hospitalier
Programme: Programme de soutien aux organismes de recherche et d'innovation (PSO) - Volet 4: Soutien au financement d'infrastructures de recherche et d'innovation
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL, Ministère de l'Économie et de l'Innovation
Type de financement: Subvention
Établissement tête: Université Laval
Du 24 mars 2022
au23 mars 2027
Financements des 2 dernières années
Chercheur d'un jour
Programme: PromoScience
Organisme(s) subventionnaire(s): Conseil de recherches en sciences naturelles et génie Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 janvier 2021
au31 décembre 2022
Chaire de recherche du Canada en neuroimmunologie
Programme: Chaires de recherche du Canada - Fonctionnement
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2016
au30 juin 2023
Développement de marqueurs génétiques de maladies rares.
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 11 février 2016
au31 mars 2024
Encadrements terminés dans les 5 dernières années
Publications des 5 dernières années
Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease Pharmacological reviews, 2022. DOI 10.1124/pharmrev.121.000400
Structural analysis of the microglia-interneuron interactions in the CA1 hippocampal area of the APP/PS1 mouse model of Alzheimer's disease The Journal of comparative neurology, 2022. DOI 10.1002/cne.25289
Reduced Melatonin Levels May Facilitate Glioblastoma Initiation in the Subventricular Zone Expert reviews in molecular medicine, 2022. DOI 10.1017/erm.2022.15
PRMT1 is required for the generation of MHC-associated microglia and remyelination in the central nervous system Life science alliance, 2022. DOI 10.26508/lsa.202201467
PDK4 Inhibition Ameliorates Melatonin Therapy by Modulating Cerebral Metabolism and Remyelination in an EAE Demyelinating Mouse Model of Multiple Sclerosis Frontiers in immunology, 2022. DOI 10.3389/fimmu.2022.862316
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression Brain, behavior, and immunity, 2022. DOI 10.1016/j.bbi.2021.07.016
Context-dependent transcriptional regulation of microglial proliferation Glia, 2022. DOI 10.1002/glia.24124
Case Report: Two Families With HPDL Related Neurodegeneration Frontiers in genetics, 2022. DOI 10.3389/fgene.2022.780764
Triggering Innate Immune Receptors as New Therapies in Alzheimer's Disease and Multiple Sclerosis Cells, 2021. DOI 10.3390/cells10082164
The Intellicage system provides a reproducible and standardized method to assess behavioral changes in cuprizone-induced demyelination mouse model Behavioural brain research, 2021. DOI 10.1016/j.bbr.2020.113039
Targeting innate immunity to protect and cure Alzheimer's disease: opportunities and pitfalls Molecular psychiatry, 2021. DOI 10.1038/s41380-021-01083-4
Selective Immunomodulatory and Neuroprotective Effects of a NOD2 Receptor Agonist on Mouse Models of Multiple Sclerosis Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021. DOI 10.1007/s13311-020-00998-0
Multifocal Cerebral Microinfarcts Modulate Early Alzheimer's Disease Pathology in a Sex-Dependent Manner Frontiers in immunology, 2021. DOI 10.3389/fimmu.2021.813536
Correction to: Selective Immunomodulatory and Neuroprotective Effects of a NOD2 Receptor Agonist on Mouse Models of Multiple Sclerosis Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021. DOI 10.1007/s13311-021-01035-4
Conditional genetic deletion of CSF1 receptor in microglia ameliorates the physiopathology of Alzheimer's disease Alzheimer's research & therapy, 2021. DOI 10.1186/s13195-020-00747-7
A founder mutation in the gene in families from Saguenay-Lac-St-Jean region affected by a pyridoxine-dependent epilepsy JIMD reports, 2021. DOI 10.1002/jmd2.12196
A Homozygous Deep Intronic Mutation Alters the Splicing of Nebulin Gene in a Patient With Nemaline Myopathy Frontiers in neurology, 2021. DOI 10.3389/fneur.2021.660113
Whole-exome sequencing identifies homozygous mutation in TTI2 in a child with primary microcephaly: a case report BMC neurology, 2020. DOI 10.1186/s12883-020-01643-1
Role of Macrophage Colony-Stimulating Factor Receptor on the Proliferation and Survival of Microglia Following Systemic Nerve and Cuprizone-Induced Injuries Frontiers in immunology, 2020. DOI 10.3389/fimmu.2020.00047
QUAKING Regulates Microexon Alternative Splicing of the Rho GTPase Pathway and Controls Microglia Homeostasis Cell reports, 2020. DOI 10.1016/j.celrep.2020.108560
Muramyl dipeptide-mediated immunomodulation on monocyte subsets exerts therapeutic effects in a mouse model of Alzheimer's disease Journal of neuroinflammation, 2020. DOI 10.1186/s12974-020-01893-3
Microglia Purinoceptor P2Y6: An Emerging Therapeutic Target in CNS Diseases Cells, 2020. DOI 10.3390/cells9071595
Inflammatory Monocytes and Neutrophils Regulate Streptococcus suis-Induced Systemic Inflammation and Disease but Are Not Critical for the Development of Central Nervous System Disease in a Mouse Model of Infection Infection and immunity, 2020. DOI 10.1128/IAI.00787-19
Beneficial Roles of Microglia and Growth Factors in MS, a Brief Review Frontiers in cellular neuroscience, 2020. DOI 10.3389/fncel.2020.00284
An Early Microglial Response Is Needed To Efficiently Control Herpes Simplex Virus Encephalitis Journal of virology, 2020. DOI 10.1128/JVI.01428-20
Alzheimer's disease: microglia targets and their modulation to promote amyloid phagocytosis and mitigate neuroinflammation Expert opinion on therapeutic targets, 2020. DOI 10.1080/14728222.2020.1738391
Ultrastructural evidence of microglial heterogeneity in Alzheimer's disease amyloid pathology Journal of neuroinflammation, 2019. DOI 10.1186/s12974-019-1473-9
Innate Immune Cells: Monocytes, Monocyte-Derived Macrophages and Microglia as Therapeutic Targets for Alzheimer's Disease and Multiple Sclerosis Frontiers in cellular neuroscience, 2019. DOI 10.3389/fncel.2019.00355
Les informations contenues dans cette page sont extraites de différents systèmes experts de l’Université Laval. Si vous constatez une erreur ou avez des questions quant aux données affichées, communiquez avec nous en écrivant à l’adresse repertoire-corps-professoral@ulaval.ca. Nous nous assurerons de rediriger votre demande à la bonne personne.